| Line 29: | Line 29: | ||
===2022: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526897/ Association of tobacco product use with chronic obstructive pulmonary disease (COPD) prevalence and incidence in Waves 1 through 5 (2013–2019) of the Population Assessment of Tobacco and Health (PATH) Study]=== | ===2022: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526897/ Association of tobacco product use with chronic obstructive pulmonary disease (COPD) prevalence and incidence in Waves 1 through 5 (2013–2019) of the Population Assessment of Tobacco and Health (PATH) Study]=== | ||
*E-cigarettes and all use categories involving cigarettes were associated with higher COPD prevalence compared to never use, reflecting, in part, the high burden of cigarette exposure in these groups. Cigarette—but not exclusive e-cigarette—use was also strongly associated with higher COPD incidence. Compared to cigarette use, only quitting tobacco was protective against COPD development. | *E-cigarettes and all use categories involving cigarettes were associated with higher COPD prevalence compared to never use, reflecting, in part, the high burden of cigarette exposure in these groups. Cigarette—but not exclusive e-cigarette—use was also strongly associated with higher COPD incidence. Compared to cigarette use, only quitting tobacco was protective against COPD development. | ||
===2022: [https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-021-00284-0 Electronic cigarettes as a harm reduction strategy among patients with COPD: protocol for an open-label two arm randomized controlled pilot trial]=== | |||
*A harm reduction approach with the goal of achieving CC switching may be a more pragmatic approach, making EC use particularly appropriate with COPD. EC represent a potentially effective harm reduction tool that is safer than smoking CC [18, 23, 24]. Smokers with COPD, however, tend to be older and may have a higher level of addiction to nicotine than the average smoker and the feasibility and preliminary effectiveness of an EC harm-reduction strategy in a COPD population has not been explored. | |||
*Our study protocol has a few limitations. First, as a pilot study the protocol is not powered to detect small differences in CPD or CAT Scores between the NRT and EC arms. Second, CAT Score is not the gold standard for the assessment of respiratory health. | |||
===2021: [https://link.springer.com/article/10.1007/s11739-021-02674-3 Health outcomes in COPD smokers using heated tobacco products: a 3-year follow-up]=== | ===2021: [https://link.springer.com/article/10.1007/s11739-021-02674-3 Health outcomes in COPD smokers using heated tobacco products: a 3-year follow-up]=== | ||
edits